12 Month Price Forecast For MCK
Distance to MCK Price Forecasts
MCK Price Momentum
๐ค Considering McKesson (MCK)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 10:48 AM UTC
MCK Analyst Ratings & Price Targets
Based on our analysis of 25 Wall Street analysts, MCK has a bullish consensus with a median price target of $675.00 (ranging from $534.20 to $729.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $603.40, the median forecast implies a 11.9% upside. This outlook is supported by 13 Buy, 3 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MCK Analyst Consensus
MCK Price Target Range
Latest MCK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MCK.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 6, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $675.00 |
Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $677.00 |
Jan 6, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $650.00 |
Dec 17, 2024 | Morgan Stanley | Erin Wright | Overweight | Maintains | $642.00 |
Dec 13, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $641.00 |
Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $713.00 |
Nov 7, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $680.00 |
Nov 7, 2024 | Baird | Eric Coldwell | Outperform | Upgrade | $688.00 |
Oct 7, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $630.00 |
Sep 25, 2024 | Deutsche Bank | George Hill | Buy | Maintains | $579.00 |
Sep 24, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $531.00 |
Sep 13, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $535.00 |
Sep 10, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $630.00 |
Sep 5, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $665.00 |
Aug 21, 2024 | JP Morgan | Lisa Gill | Overweight | Maintains | $661.00 |
Aug 8, 2024 | Barclays | Steve Valiquette | Overweight | Maintains | $616.00 |
Aug 8, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $630.00 |
Aug 8, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $671.00 |
Jul 19, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $670.00 |
Jul 9, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $694.00 |
Stocks Similar to McKesson Corp
The following stocks are similar to McKesson based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
McKesson Corp (MCK) Financial Data
McKesson Corp has a market capitalization of $75.29B with a P/E ratio of 27.6x. The company generates $330.19B in trailing twelve-month revenue with a 0.8% profit margin.
Revenue growth is +21.3% quarter-over-quarter, while maintaining an operating margin of +0.8% and return on equity of -187.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

McKesson Corp (MCK) Company Overview
About McKesson Corp
Delivers comprehensive healthcare services globally.
The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. It generates revenue primarily by distributing pharmaceutical products, offering technology and consulting services, and providing logistics and supply chain solutions to healthcare providers and partners.
Founded in 1833 and headquartered in Irving, Texas, McKesson has a long-standing presence in the healthcare industry. Its diverse portfolio allows it to cater to various healthcare needs, making it a crucial player in improving medication access and healthcare delivery.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
45,000
CEO
Mr. Brian S. Tyler Ph.D.
Country
United States
IPO Year
1994
Website
www.mckesson.comMcKesson Corp (MCK) Latest News & Analysis
McKesson reported third-quarter revenue below estimates, impacted by weaker-than-expected sales in its U.S. pharmaceutical segment, including branded and specialty drugs.
McKesson's revenue miss indicates weaker demand in its U.S. pharmaceutical segment, potentially affecting future earnings and investor confidence in the company's growth prospects.
McKesson Exceeds EPS, Q3 Profit Surges
6 days agoMcKesson (MCK) reported Q3 fiscal 2025 results, exceeding earnings expectations with an adjusted EPS of $8.03, slightly above the forecast of $8.01.
McKesson's earnings beat indicates strong operational performance, potentially boosting investor confidence and impacting stock performance positively. Mixed results may signal volatility ahead.
McKesson Corporation (NYSE:MCK) will hold its Q3 2025 earnings conference call on February 5, 2025, at 4:30 PM ET, featuring key executives and analysts from major firms.
The earnings call will provide insights into McKesson's financial performance and strategy, influencing stock valuation and investor sentiment in the healthcare sector.
McKesson Corporation (NYSE: MCK) released its fiscal 2025 Q3 financial results. A live webcast of the earnings call is scheduled for February 5th at 4:30 PM ET.
McKesson's Q3 results may impact stock performance and investor sentiment, with key insights expected during the earnings call that could influence future forecasts and market positioning.
McKesson (MCK) reported quarterly earnings of $8.03 per share, slightly below the Zacks estimate of $8.04, but up from $7.74 per share year-over-year.
McKesson's earnings miss indicates potential challenges in performance despite year-over-year growth, which could impact investor sentiment and stock valuation.
McKesson's Q4 2024 performance shows key metrics against Wall Street estimates and year-ago values, indicating a need for detailed analysis for investors.
Comparing McKesson's performance metrics to Wall Street estimates and previous year values can reveal growth trends, operational efficiency, and potential stock price movements.
Frequently Asked Questions About MCK Stock
What is McKesson Corp's (MCK) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, McKesson Corp (MCK) has a median price target of $675.00. The highest price target is $729.00 and the lowest is $534.20.
Is MCK stock a good investment in 2025?
According to current analyst ratings, MCK has 13 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $603.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MCK stock?
Wall Street analysts predict MCK stock could reach $675.00 in the next 12 months. This represents a 11.9% increase from the current price of $603.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is McKesson Corp's business model?
The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. It generates revenue primarily by distributing pharmaceutical products, offering technology and consulting services, and providing logistics and supply chain solutions to healthcare providers and partners.
What is the highest forecasted price for MCK McKesson Corp?
The highest price target for MCK is $729.00 from at , which represents a 20.8% increase from the current price of $603.40.
What is the lowest forecasted price for MCK McKesson Corp?
The lowest price target for MCK is $534.20 from at , which represents a -11.5% decrease from the current price of $603.40.
What is the overall MCK consensus from analysts for McKesson Corp?
The overall analyst consensus for MCK is bullish. Out of 25 Wall Street analysts, 13 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $675.00.
How accurate are MCK stock price projections?
Stock price projections, including those for McKesson Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.